Email

support@elyxaminos.com

FREE Shipping on orders over $200 USD

Tesamorelin 20mg

$ 952,000

GHRH Analogue · Visceral Fat · Endogenous IGF-1 · Research Only

  • Tesamorelin 20mg lyophilized for reconstitution with 2ml of bacteriostatic water
  • Concentration: 10,000 mcg/ml · U-100 Dose: 100 mcg/u
  • SubQ route · Refrigeration 2-8°C
  • Research material only. No FDA-approved human use.

In stock

Global Elite Shipping

Fast shipments from our logistics center in the USA to worldwide.

Guaranteed Purity

Each batch includes a Certificate of Analysis (COA) for research grade.

Secure & Private Payment

Encrypted transactions to protect your cellular health investment.

Description

Tesamorelin 20mg

GHRH Analog · Visceral Fat · Endogenous IGF-1 · Research Only

What is it and how does it work?

Tesamorelin is a stabilized synthetic analog of human growth hormone releasing factor (GHRH). It binds to the GHRH-R receptor on pituitary somatotropes and stimulates pulsatile release of endogenous growth hormone, with documented increase in serum IGF-1 in clinical studies. The literature describes a preferential effect on visceral abdominal adipose fat in HIV-associated lipodystrophy cohorts.

Clinical evidence: Falutz et al. (NEJM 2007, PMID 17984164) in patients with HIV-associated lipodystrophy documented 15-20% visceral fat reduction with 2 mg/day SubQ × 26 weeks. Stanley et al. (JCI 2014, PMID 24911148) reported improvement of hepatic steatosis in non-alcoholic fatty liver disease. Research material only — no FDA-approved human use outside the specific indication of HIV lipodystrophy (Egrifta).

Reconstitution

  • Vial 10 mg lyophilized
  • Bacteriostatic water: 2 ml
  • Resulting concentration: 10,000 mcg/ml
  • Per unit U-100: 50 mcg · verification: 5,000 ÷ 100 = 50 mcg/u ✓
  • Conservation Refrigerate 2–8°C · Use within 28–30 days after reconstituting

Documented evidence

  • Falutz J et al., NEJM 2007 (PMID 17984164) — Tesamorelin 2mg/day SubQ × 26 weeks reduces visceral fat in HIV lipodystrophy
  • Stanley TL et al., JCI 2014 (PMID 24911148) — Improvement of hepatic steatosis
  • Adrian S et al., Clin Infect Dis 2018 — improvement in IGF-1 and body composition

Practical notes

  • Route documented in clinical literature: SubQ once daily (typically at night)
  • The effect on IGF-1 is dose-dependent; literature reports IGF-1 monitoring every 6-12 weeks
  • Research stack: Tesamorelin + CJC/Ipa amplifies the GH axis; with BPC-157 for tissue regeneration

Contraindications and precautions

  • Research material only. No FDA-approved human use outside Egrifta® for HIV lipodystrophy. No established safety data for other uses. Not for human use.

Research material only. No FDA-approved human use. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.

Legal Notice

All products are sold in powder (lyophilized) form and require reconstitution with a suitable diluent for research purposes only. Laboratory supplies (e.g., syringes, bacteriostatic water, etc.) are not included. Dosage instructions are not provided.

We comply with all local and national laws and regulations related to product sales. exclusively for research.
We are not a pharmacy, nor do we offer, promote, or provide any advice for human or animal consumption.

Please carefully review our terms and conditions Before making a purchase on our website.

You must be over 21 years old and a licensed research professional.

When clicking on “I accept”, you confirm that you have read and accepted the Terms and Conditions set forth above.

x
Cart
Your cart is empty
Let's go shopping!
Start shopping